A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because of cardiovascular toxicity. Transdermal oestrogen (tE2) patches are a potential alternative ADT, supressing testosterone without the associated oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) and avoiding cardiovascular toxicity, and we here describe their evaluation in men ...
Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: D.C. Gilbert, M. Nankivell, H. Rush, N.W. Clarke, S. Mangar, A. Al-hasso, S. Rosen, R. Kockelbergh, S.K. Sundaram, S. Dixit, M. Laniado, N. McPhail, A. Shaheen, S. Brown, J. Gale, J. Deighan, J. Marshall, T. Duong, A. Macnair, A. Griffiths, C.L. Amos, M.R Tags: Original Article Source Type: research
A Repurposing Programme Evaluating Repurposing Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because of cardiovascular toxicity. Transdermal oestrogen (tE2) patches are a potential alternative ADT, supressing testosterone without the associated oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) and avoiding cardiovascular toxicity, and we here describe their evaluation in men ...
Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: D.C. Gilbert, M. Nankivell, H. Rush, N.W. Clarke, S. Mangar, A. Al-hasso, S. Rosen, R. Kockelbergh, S.K. Sundaram, S. Dixit, M. Laniado, N. McPhail, A. Shaheen, S. Brown, J. Gale, J. Deighan, J. Marshall, T. Duong, A. Macnair, A. Griffiths, C.L. Amos, M.R Tags: Original Article Source Type: research
In Response to the Correspondence to the Editor Regarding ʻExtra-mandibular Osteoradionecrosis After the Treatment of Head and Neck Cancer’
Sir — We thank Yilmaz and Topkan [1] for taking an interest in the article and for their valuable comments. (Source: Clinical Oncology)
Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: P.D.E. Kovarik, R. Patil, M. Jackson, C. Kelly, N. West, M.S. Iqbal Tags: Letter Source Type: research
A repurposing programme evaluating repurposing transdermal Estradiol (tE2) patches for the treatment of prostate cancer within the PATCH and STAMPEDE trials: Current results and adapting trial design
Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing hormone analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen and are associated with significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because of cardiovascular toxicity. Transdermal oestrogen (tE2) patches are an alternative ADT, supressing testosterone without the associated oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) and avoiding cardiovascular toxicity. (Source: Clinical Oncology)
Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: Duncan C. Gilbert, Matthew Nankivell, Hannah Rush, Noel W. Clarke, Stephen Mangar, Abdullah Al-hasso, Stuart Rosen, Roger Kockelbergh, Subramaniam Kananga Sundaram, Sanjay Dixit, Marc Laniado, Neil McPhail, Ahmed Shaheen, Simon Brown, Joanna Gale, John De Tags: Original Article Source Type: research
In response to the correspondence to the Editor regarding 'Extra-mandibular Osteoradionecrosis after the Treatment of Head and Neck Cancer ’
(Source: Clinical Oncology)
Source: Clinical Oncology - November 7, 2023 Category: Radiology Authors: P.D.E. Kovarik, R. Patil, M. Jackson, C. Kelly, N. West, M.S. Iqbal Tags: Letter Source Type: research
Correlation of the Geriatric Assessment with Overall Survival in Older Patients with Cancer
Global guidelines recommend that all older patients with cancer receiving chemotherapy should undergo a geriatric assessment. However, utilisation of the geriatric assessment is often constrained by its time-intensive nature, which limits its adoption in settings with limited resources and high demand. There is a lack of evidence correlating the results of the geriatric assessment with survival from the Indian subcontinent. Therefore, the aims of the present study were to assess the impact of the geriatric assessment on survival in older Indian patients with cancer and to identify the factors associated with survival in th...
Source: Clinical Oncology - November 6, 2023 Category: Radiology Authors: A.R. Rao, V. Noronha, A. Ramaswamy, A. Kumar, A. Pillai, S. Gattani, A. Sehgal, S. Kumar, R. Castelino, R. Dhekle, J. Krishnamurthy, S. Mahajan, A. Daptardar, L. Sonkusare, J. Deodhar, N. Ansari, M. Vagal, P. Mahajan, S. Timmanpyati, M. Nookala, A. Chitre Tags: Original Article Source Type: research
Image-guided Interstitial Brachytherapy in the Treatment of Primary and Recurrent Vulvovaginal Gynaecological Malignancies
To evaluate the use, outcomes and toxicities of high dose rate brachytherapy (HDRB) to the vulvovaginal region in previously irradiated and radiotherapy-na ïve patients for primary or recurrent gynaecological malignancies. (Source: Clinical Oncology)
Source: Clinical Oncology - October 28, 2023 Category: Radiology Authors: A. Sarwar, L. Syed, K. Patel, I. Reid, E. Abonyi, N. Banas, G. Lowe, L. Bryant, P. Hoskin Tags: Original Article Source Type: research
Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results from the KNOW-OC Survey
New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes. (Source: Clinical Oncology)
Source: Clinical Oncology - October 28, 2023 Category: Radiology Authors: C. Fotopoulou, M. Hall, R. Lord, R. Miller, S. Sundar, N. Roebuck, L. Fildes, A. Wesselbaum, S. McCormack, J. Hickey, J. Ledermann Tags: Original Article Source Type: research
Online Oncology Careers Events to Attract the Future Oncology Medical Workforce: an Exemplar Event and Review of the Literature
There are too few oncologists to meet the increasing burden imposed by the rising incidence of cancer. This results from issues with the retention of established oncologists and longstanding challenges to the recruitment of adequate numbers of trainees. To counter this, the British Oncology Network for Undergraduate Societies (BONUS) devised an online oncology careers event for medical students and junior doctors who are yet to select a specialty. (Source: Clinical Oncology)
Source: Clinical Oncology - October 26, 2023 Category: Radiology Authors: E.G. Khoury, K. Lynch-Kelly, T. Fulton-Ward, S. Heritage, A. Devasar, C.M. Jones Tags: Original Article Source Type: research
Multidisciplinary management of phyllodes tumours and breast sarcoma: a cross-sectional survey of clinical practice across the United Kingdom and Ireland
Phyllodes tumours and breast sarcomas are uncommon tumours and their rarity poses significant challenges in diagnosis and management. This cross-sectional study was conducted to evaluate the multidisciplinary clinical practice for these tumours across the UK and Ireland, with the aim of identifying gaps in knowledge and providing direction for establishing national guidelines. (Source: Clinical Oncology)
Source: Clinical Oncology - October 20, 2023 Category: Radiology Authors: Mai K. Bishr, Jenny Banks, Mohamed S. Abdelaziz, Marwa Badawi, Peter W. Crane, Urszula Joanna Donigiewicz, Mohamed Elkorety, Mina Girgis, Alex Humphreys, Jen Isherwood, Jennifer Kahan, Stephen Keelan, Ebba K. Lindqvist, Ioanna Nixon, Helena Sackey, Carl S Tags: Original Article Source Type: research
Single-fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic Cancers
Stereotactic ablative body radiotherapy (SABR) consists of delivering high doses of ionising radiation, typically across three to eight fractions with high precision and conformity. SABR has become increasingly commonplace throughout the last quarter of a century and is offered for the treatment of various primary and metastatic tumour types. Delivering SABR in a single fraction has arisen as an appealing possibility for several reasons. These include fewer hospital visits, greater patient convenience, improved sustainability and lower costs. (Source: Clinical Oncology)
Source: Clinical Oncology - October 9, 2023 Category: Radiology Authors: H. Greenwood, J. Hassan, K. Fife, T. Ajithkumar, K. Thippu Jayaprakash Tags: Overview Source Type: research
Risk Factors for Locoregional Recurrence and Distant Metastasis in 143 Patients with Adenoid Cystic Carcinoma of the External Auditory Canal
This study aimed to evaluate the risk factors for locoregional recurrence (LRR) and distant metastasis in patients with ACC of the external auditory canal (EAC). (Source: Clinical Oncology)
Source: Clinical Oncology - October 6, 2023 Category: Radiology Authors: Yisi Feng, Feitian Li, Jing Wang, Liang Xu, Dedi Kong, Wenfang Sun, Xunbei Shi, Wei Li, Qianru Wu, Yibo Zhang, Chunfu Dai Tags: Original Article Source Type: research
RCR Meetings
(Source: Clinical Oncology)
Source: Clinical Oncology - October 4, 2023 Category: Radiology Source Type: research
OncoFlash – Research Updates in a Flash! (Nov 2023)
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. Nutting C et al. Lancet Oncol 2023 [1]. (Source: Clinical Oncology)
Source: Clinical Oncology - October 4, 2023 Category: Radiology Authors: C. Lorimer, K.T. Jayaprakash Source Type: research
Long-term Overall Survival after External Beam Radiotherapy for Localised Prostate Cancer
Knowledge on survival probabilities is essential for determining optimal treatment strategies. We studied overall survival and associated prognostic factors in Dutch patients with localised prostate cancer (PCa) selected for external beam radiotherapy. (Source: Clinical Oncology)
Source: Clinical Oncology - October 3, 2023 Category: Radiology Authors: M.-C. Jahrei β, L. Incrocci, M. Dirkx, K.C. de Vries, K.K.H. Aben, C. Bangma, W.D. Heemsbergen Tags: Original Article Source Type: research
